ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 166 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2018. The put-call ratio across all filers is 9.02 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $32,691 | -30.6% | 917 | -10.2% | 0.00% | 0.0% |
| Q2 2023 | $47,099 | +64.0% | 1,021 | +42.6% | 0.00% | 0.0% |
| Q1 2023 | $28,712 | -57.6% | 716 | -51.0% | 0.00% | -50.0% |
| Q4 2022 | $67,734 | +170.9% | 1,462 | +143.7% | 0.00% | +100.0% |
| Q3 2022 | $25,000 | +78.6% | 600 | +151.0% | 0.00% | – |
| Q2 2022 | $14,000 | +40.0% | 239 | +69.5% | 0.00% | – |
| Q1 2022 | $10,000 | +25.0% | 141 | +50.0% | 0.00% | – |
| Q4 2021 | $8,000 | +300.0% | 94 | +248.1% | 0.00% | – |
| Q3 2021 | $2,000 | +100.0% | 27 | +350.0% | 0.00% | – |
| Q2 2021 | $1,000 | -50.0% | 6 | -64.7% | 0.00% | – |
| Q1 2021 | $2,000 | -33.3% | 17 | -22.7% | 0.00% | – |
| Q4 2020 | $3,000 | – | 22 | +266.7% | 0.00% | – |
| Q3 2020 | $0 | – | 6 | +500.0% | 0.00% | – |
| Q3 2018 | $0 | – | 1 | 0.0% | 0.00% | – |
| Q2 2018 | $0 | – | 1 | 0.0% | 0.00% | – |
| Q1 2018 | $0 | – | 1 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |